I
N 1989, the European Working Party on High Blood Pressure in the Elderly started the double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial to test the hypothesis that antihypertensive drug treatment would reduce the incidence of fatal and nonfatal stroke. 1 Active treatment was initiated with the dihydropyridine calcium channel blocker nitrendipine, 2 with the possible addition of enalapril, hydrochlorothiazide, or both drugs. In the recently published intentionto-treat analysis of the Syst-Eur trial, 3 active treatment decreased the overall stroke rate from 13.7 to 7.9 end points per 1000 patient-years (−42%, P = .003) and the incidence of all cardiovascular complications from 33.9 to 23.3 end points per 1000 patient-years (−31%, PϽ.001). At the rates observed in the placebo group, treating 1000 patients for 5 years could prevent 29 strokes or 53 major cardiovascular end points. 3 Whereas analysis by intention to treat reduces bias due to selective withdrawals, it may underestimate the true effects of treatment by including all end points in the calculations, regardless of whether they occurred on randomized therapy or on openlabel medication.
This article expands the first Syst-Eur report. 3 It explores (1) whether the benefits of active treatment were evenly distributed across 4 strata, prospectively defined according to sex and previous cardiovascular complications 1 ; (2) the morbidity and mortality results were influenced by age, level of initial blood pressure, or smoking or drinking habits at randomization; and (3) whether the estimates of benefit remained consistent, if instead of an intention-to-treat approach, a per-protocol approach was applied.
RESULTS

PREDICTORS OF END POINTS BY INTENTION TO TREAT
In the 4695 randomized patients ( Figure 1 ) the median follow-up by intention to treat was 2.0 years (range, 1-97 months). The numbers of patient-years in the placebo and active treatment groups were 5709 and 5995, respectively. At median follow-up, the sitting systolic and diastolic blood pressures had fallen by a mean (±SD) of 13 ± 17 and 2 ± 8 mm Hg, respectively, in the placebo group and by 23 ± 16 and 7 ± 8 mm Hg in the active treatment group. The differences in systolic and diastolic blood pressures between the 2 groups then averaged 10.1 mm Hg (95% confidence interval [CI], mm Hg) and 4.5 mm Hg (95% CI, 3.9-5.1 mm Hg), respectively. The analysis by intention to treat, both before ( Table 1) and after ( Table 2) adjustment for significant covariates, showed that active treatment had reduced the incidence of fatal and nonfatal stroke (PϽ.01), fatal and nonfatal cardiac complications (PϽ.05), and all fatal and nonfatal cardiovascular end points (PϽ.001). Cardiovascular mortality also showed a tendency to decrease (P = .07).
METHODS
STUDY DESIGN
The protocol of the Syst-Eur trial 1, 3 was approved by the ethics committees of the University of Leuven, Belgium, and the participating centers and implemented according to the principles outlined in the Helsinki declaration. 4 Patients were eligible (1) if they were at least 60 years old; (2) if on placebo during the run-in phase their sitting systolic blood pressure ranged from 160 to 219 mm Hg, with diastolic blood pressure below 95 mm Hg; (3) if their standing systolic blood pressure was 140 mm Hg or more; (4) if they consented to be enrolled; and (5) if long-term follow-up was possible. The blood pressure criteria for entry were based on the averages of 6 sitting and 6 standing readings, ie, 2 in each position at 3 baseline visits 1 month apart. Patients could not be enrolled if systolic hypertension was secondary to a disorder that needed specific medical or surgical treatment. Other exclusion criteria were retinal hemorrhage or papilledema; congestive heart failure; dissecting aortic aneurysm; a serum creatinine concentration at presentation of 180 µmol/L (2 mg/dL) or higher; a history of severe nosebleeds, stroke, or myocardial infarction in the year before the study; dementia or substance abuse; any condition prohibiting a sitting or standing position; or severe concomitant cardiovascular or noncardiovascular disease.
Eligible patients were prospectively stratified by center, sex, and previous cardiovascular complications and thereafter randomized to double-blind treatment with active medication or placebo by means of a computerized random function. Patients with a Sokolow-Lyon electrocardiographic voltage index of 35 mm or more 5 were included in the group with cardiovascular complications at entry. After randomization, active treatment was initiated with nitrendipine (10-40 mg/d) . If necessary, the calcium channel blocker was combined with or replaced by enalapril maleate (5-20 mg/d) or hydrochlorothiazide (12.5-25 mg/d) or both drugs. The patients in the control group received matching placebos. The study medications were stepwise titrated and combined to reduce sitting systolic blood pressure by 20 mm Hg or more to less than 150 mm Hg. 1 Patients withdrawing from double-blind treatment remained in open follow-up.
1 During double-blind treatment and supervised open follow-up, clinic visits were scheduled at 3-month intervals. For patients who withdrew from double-blind treatment and for whom regular follow-up was impossible, information was collected annually (nonsupervised open follow-up). Patients without any report within the year before the trial stopped were counted as unavailable for follow-up but were included in the analysis up to the most recent evaluation of their health status.
DEFINITION AND VALIDATION OF END POINTS
The End Point Committee, which was unaware of the patients' treatment, identified all major end points by reviewing the patients' files and other source documents, by requesting detailed written information from the investigators, or by both approaches. Diseases were coded according to the International Classification of Diseases, . 6 Stroke, the primary end point in the Syst-Eur trial, was defined as a neurologic deficit continuing for more than 24 hours or leading to death with no apparent cause other than vascular. The diagnosis of acute myocardial infarction rested on 2 of the following 3 disorders: typical chest pain, electrocardiographic changes, or increased cardiac enzyme levels. Myocardial infarction did not include silent myocardial infarction. Congestive heart failure required the presence of 3 conditions, namely, symptoms, such as dyspnea; clinical signs, such as ankle edema or rales; and the necessity of treatment with diuretics, vasodilators, or antihypertensive drugs. Sudden death included any death of unknown origin occurring instantly or within 24 hours of the onset of acute symptoms, as well as unattended death for which no likely cause could be established by autopsy or recent medical history. Cardiac end points included fatal and nonfatal heart failure, fatal and nonfatal myocardial infarction, and sudden death.
STATISTICAL ANALYSIS
Database management and statistical analysis were performed with SAS software (SAS Institute Inc, Cary, NC). Only 2-sided statistical tests were used. Comparisons of means and proportions relied on the standard normal z test and the 2 statistic, respectively. Relative risk was assessed by single and multiple Cox regression. 7 Survival curves were compared using Kaplan-Meier survival function estimates and the log-rank test. The analysis by intention to treat included all end points occurring during doubleblind and open follow-up, regardless of whether the patients were taking the treatment to which they had been randomized. The per-protocol analysis included only the end points that intervened during the double-blind phase of the trial.
Sex and Previous Cardiovascular Complications
Before randomization, the patients had been prospectively stratified by sex and previous cardiovascular complications. The trial included 1557 men (33.2%), 3138 women (66.8%), 1402 patients with previous cardiovascular complications (29.9%) , and 3293 patients without such complications (70.1%). The 4 strata were equally represented in the 2 arms of the trial. Most cardiovascular complications at randomization were mild. Only 58 patients (4.1% of those with cardiovascular complications) had a history of stroke and 163 (11.6%) a history of myocardial infarction. The other patients with cardiovascular complications at entry had symptoms or signs suggestive of coronary heart disease (n = 412), symptoms or signs of cerebrovascular disease (n = 45), electrocardiographic changes compatible with left ventricular hypertrophy (n = 614), or a combination of these conditions or other vascular, retinal, or renal lesions (n = 110).
Men and patients with cardiovascular complications at entry experienced significantly more end points during follow-up (Table 1) . With adjustments applied for the covariates listed in Table 2 , male sex did not behave as a significant predictor of fatal and nonfatal stroke (relative hazard rate [RHR], 1.17; 95% CI, 0.81-1.70; P = .40) or of fatal and nonfatal cardiac end points (RHR, 1.28; 95% CI, 0.95-1.17; P = .10). Further analysis showed that the benefits of active treatment were evenly distributed across the sex and cardiovascular complication groups. In multiple Cox regression, the P values for the interactions with treatment ranged from .62 to .86 for sex and from .26 to .87 for cardiovascular complications.
Age
Age at randomization averaged 70.2 (6.7) years. In single (Table 1 ) and multiple (Table 2 ) regression, age was a strong predictor of outcome. Plots of the crude RHRs in 3 age strata (60-69, 70-79, and Ն80 years) suggested that for total and cardiovascular mortality (Figure 2) but not for the combined fatal and nonfatal end points (Figure 3 ), the effects of active treatment were attenuated in patients over the age of 80 years. In Cox regression (Figure 4) , with adjustments applied for the significant covariates listed in Table 2 , the treatment ϫ age interaction term was significant (P = .009) for total mortality (RHR, 1.04; 95% CI, 1.01-1.08) and nearly significant (P = .09) for cardiovascular mortality (RHR, 1.04; 95% CI, 0.99-1.09). In contrast, the treatment ϫ age interaction terms for the combined fatal and nonfatal end points were not statistically significant ( Figure 5 ).
Systolic and Diastolic Blood Pressure
At randomization, the sitting blood pressure averaged 173.8 ± 10.0 mm Hg systolic and 85.5 ± 5.9 mm Hg diastolic. In single regression (Table 1) , all end points except fatal and nonfatalcardiaccomplicationswerepositivelycorrelatedwith systolic blood pressure. However, after adjustment for the covariates listed in Table 2 , systolic blood pressure predicted only stroke incidence. Plots of the crude RHRs in 3 strata *Because the relative hazard rates were calculated by stepwise Cox regression with treatment forced into the model, they are automatically adjusted for randomization to active treatment and for all significant covariates listed in the table. Diastolic blood pressure at randomization and drinking alcohol were not independently and significantly correlated with outcome. NS indicates not significant. See Table 1 for explanation of the remaining footnote symbols.
according to the systolic blood pressure at randomization (160-169, 170-179, and Ն180 mm Hg) did not show a consistent trend (Figures 2 and 3) . However, for total mortality, after adjustment for significant covariates (Table 2) , the treatment ϫ systolic blood pressure interaction term was significant (P = .05) and suggested greater benefit at higher initial systolic blood pressure (Figure 4) .
In single regression (Table 1) , a higher diastolic blood pressure was associated with lower total (PϽ.001) and cardiovascular (PϽ.001) mortality and fewer combined fatal and nonfatal end points (P, Ͻ.001 to .02). However, after adjustment for the significant covariates listed in Table 2 , these associations weakened to a nonsignificant level (P, .16 to .93) and were not influenced by treatment status (P, .14 to .82).
Eastern vs Western European Extraction
Of the 4695 patients, 1994 (42.5%) had been recruited in Eastern Europe (Belorussia, Bulgaria, Croatia, Czech Republic, Estonia, Lithuania, Poland, Romania, Slovakia, Slovenia, Russian Federation), where after adjustment for significant covariates (Table 2) , total mortality was significantly higher than in Western Europe (Belgium, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Spain, United Kingdom) and Israel. Furthermore, with these adjustments applied, the interaction term with active treatment was nonsignificant (P = .53). This was also the case for cardiovascular (P = .08) mortality and the other combined fatal and nonfatal end points (P, .34 to .61).
Smoking and Drinking Habits
At randomization, the median daily use of tobacco was 15 cigarettes in 231 male smokers (5th-95th percentile, 3-50 cigarettes) and 10 cigarettes (5th-95th percentile, 2-30 cigarettes) in 112 female smokers. Both before (Table 1) and after ( Table 2 ) adjustment for significant covariates, smoking predicted total and cardiovascular mortality and combinedfatalandnonfatalcardiovascularandcardiacendpoints. With adjustments for significant covariates (Table 2) , Cox regression showed a significant interaction for stroke (P = .01) between treatment and smoking. The RHR for active treatment compared with placebo was 0.47 (95% CI, 0.32-0.69) in nonsmokers but 2.75 (95% CI, 0.73-10.4) in smokers. The percentage of smokers was similar among the stroke patients (8.9% [11/124] ) and the other participants (7.3% [332/4571] ).
At randomization, 393 men and 132 women consumed at least 1 U/d of an alcoholic beverage, ie, 1 glass of beer, wine, aperitif, fortified wine, or liquor. Their median daily consumption of alcohol was 19 g (5th-95th percentile: 10-54 g) and 14 g (5th-95th percentile: 10-36 g), respectively. Alcohol intake was not correlated with outcome either before (Table 1) or after ( Table 2 ) adjustment for covariates (P, .14 to .64 and .19 to .85, respectively) . In multiple Cox regression, P values for the interaction terms between treatment and drinking alcohol ranged from .16 to .99.
PER-PROTOCOL ANALYSIS
In the per-protocol analysis, the number of patient-years in the placebo and active treatment groups amounted to 4508 In the placebo group, these numbers were 800 (92.4%), 477 (55.1%), and 297 (34.2%), respectively. At median follow-up, the sitting systolic and diastolic blood pressures had fallen by 13 ± 16 and 2 ± 7 mm Hg, respectively, in the placebo group and by 25 ± 15 and 7 ± 8 mm Hg in the active treatment group. The betweengroup differences in sitting systolic and diastolic blood pressures then averaged 11.6 mm Hg (95% CI, 10.1-13.0 mm Hg) and 5.3 mm Hg (95% CI, 4.5-6.0 mm Hg), respectively. Of the patients remaining on double-blind medication, 84 died in the placebo group and 71 in the active treatment group. The cumulative total mortality in the per-protocol analysis amounted to 18.6 and 13.7 deaths per 1000 patientyears, respectively ( Table 3) . Active treatment reduced total mortality by 26% (P = .05). A similar trend was observed for fatal myocardial infarction (−60%, P = .08). Although cerebrovascular (−31%, P = .36) and cardiac (−20%, P = .34) mortality rates were lower on active treatment, the wide confidence intervals for these fatal outcomes did not exclude thepossibilityofnoeffectofantihypertensivedrugtreatment.
In general, the per-protocol analysis of the nonfatal end points and the combined fatal and nonfatal end points produced results similar to those in the intention-to-treat approach (Table 4) . Among the patients who remained in double-blindfollow-up,activetreatmentreducedtotalstroke by 44% (P = .004) and nonfatal stroke by 48% (P = .005). In the active treatment group, nonfatal cardiac end points decreased by 29% (P = .07). A similar trend was observed for fatal and nonfatal cases of heart failure (−35%, P = .06). All fatalandnonfatalcardiacendpoints,includingsuddendeath, declined by 26% (P = .05). Active treatment reduced all fatalandnonfatalcardiovascularendpointsby32%(PϽ.001).
In terms of absolute benefit, the per-protocol analysis suggested that at the rates observed in the placebo group, treating 1000 patients for 5 years would prevent 24 deaths, 54 major cardiovascular end points, 29 fatal and nonfatal strokes, 24 nonfatal strokes, 25 fatal and nonfatal cardiac end points, or 18 nonfatal cardiac end points.
COMMENT
Stratification by sex and previous cardiovascular complications allowed us to test whether these characteristics had influenced outcome in the Syst-Eur trial. As expected, men were at higher risk than women. Voltage criteria compatible with left ventricular hypertrophy 5 accounted for the majority of cardiovascular complications at entry. Subjects stratified into this group died or experienced major cardiovascular end points at nearly twice the rate observed in the other patients. Men and women and patients with and without previous cardiovascular complications all benefited from antihypertensive drug treatment.
The interaction terms between active treatment and age suggested that antihypertensive drug treatment did not postpone death in patients older than 75 to 80 years ( Figure 4 ) but probably still prevented cardiovascular complications, stroke, and cardiac end points in the very old ( Figure 5 ). Age at recruitment ranged from 60 to 96 years in 6 randomized outcome trials [8] [9] [10] [11] [12] [13] of antihypertensive drug treatment (for a review, see Thijs et al 14 ) . In the trial conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE), a significant (P = .05) treatment ϫ age interaction suggested that cardiovascular mortality decreased less on active treatment in the oldest patients, especially beyond *CI indicates confidence interval. †The benefit of active treatment is expressed as the percentage reduction of the rate in the placebo group (relative benefit) and the number of deaths prevented by treating 1000 patients for 5 years, assuming the same risks as in the placebo group (absolute benefit).
‡For the difference between active and placebo treatment. §This refers to previously reported differences in the placebo group by intention to treat.
80 years. 15 In the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension), 10 compared with the control group, older patients randomized to active treatment experienced less reduction in deaths from stroke, myocardial infarction, or other cardiovascular causes. The upper 95% confidencelimitoftherelativeriskcrossedunitybyage73years. 10 The findings in 650 patients aged 80 years or older randomized in the Systolic Hypertension in the Elderly Program (SHEP) 16, 17 are in contrast with those of the EWPHE 15 and STOP-Hypertension 10 trials and with the mortality results in the present study (Figure 4) . Indeed, in the SHEP trial, 16, 17 the relative risk of stroke on active treatment compared with placebo was 0.51 (95% CI, 0.29-0.89). In view of the remaining uncertainty, the Hypertension in the Very Elderly Trial (HYVET) is currently investigating the potential benefit of antihypertensive drug treatment on stroke and other cardiovascular end points in patients over the age of 80 years. 18 Until the results of this trial are reported, clinicians may consider the possible reduction of nonfatal stroke as the main reason to prescribe antihypertensive agents to very old patients, in whom this complication often undermines precarious autonomy and leads to institutionalization.
In the present analysis, the benefits of active antihypertensive treatment were observed regardless of the blood pressurelevelatentry.Ifanything,totalmortalitydeclinedslightly more on active treatment when the initial systolic blood pressure was higher (Figure 4) . Statistical analyses of the EWPHE study 15 and the Medical Research Council 12 trial, which controlled for possible confounders, such as sex, age, and previous cardiovascular complications, did not demonstrate an interaction between the blood pressure level at randomization and the benefit derived from treatment. The SHEP investigators reported that in proportional hazard regression, using systolic blood pressure as a continuous variable, the favorable trend in stroke incidence for the active treatment group compared with the placebo group prevailed irrespective of the baseline systolic blood pressure. 16, 17 The P value for interaction was . 13. 17,19 This conclusion was reinforced by similar findings for nonfatal myocardial infarction combined with death from coronary heart disease (P = .85), coronary heart disease (P = .81), and all cardiovascular complications (P = .44). 19 The finding that total mortality in the active treatment group tended to decrease with higher initial systolic blood pressure (Figure 4 ) is in line with the findings of several reports, [20] [21] [22] which have suggested that pulse pressure behaves as an independent cardiovascular risk factor.Indeed,pulsepressureincreaseswithhighersystolicblood pressure and lower diastolic blood pressure and was by definition at least 65 mm Hg in the Syst-Eur patients.
ActivetreatmentintheSyst-Eurtrialdecreasedallstrokes by 53% in nonsmokers but did not affect the stroke rate in smokers, who represented less than 8% of the whole trial population. In some studies 12, [23] [24] [25] the beneficial effects of ␤-blockade seemed to be limited to nonsmokers, whereas in other trials the effects were either similar 26 in smokers and nonsmokers or tended to be even greater 27 in smokers. Several mechanisms have been proposed to explain the apparently lesser reduction of cardiovascular complications by nonselective ␤-blockade in hypertensive smokers. The catecholamines released by nicotine 28 may exert an increased pressor effect when nonselective ␤-blockers, such as propranolol, inhibit the vasodilating ␤-receptors, while leaving the vasoconstricting ␣-receptors unopposed. However, lesser protection in smokers has been found not only with nonselective ␤-blockers [23] [24] [25] but also with selective ␤-blockers, 12 with thiazides compared with metoprolol, 27, 29 and nowintheSyst-Eurtrialalsowiththecalciumchannelblocker nitrendipine. 3 These contradictory findings are likely to reflect random variability or confounding in subgroup analyses. This particularly applies to the Syst-Eur trial, in which *CI indicates confidence interval. †The benefit of active treatment is expressed as the percentage reduction of the rate in placebo group (relative benefit) and the number of end points prevented by treating 1000 patients for 5 years, assuming the same risk as in the placebo group (absolute benefit).
3
The number of cardiac end points may not add to the total because some patients experienced more than 1 nonfatal complication. ¶Included fatal and nonfatal heart failure, fatal and nonfatal myocardial infarction, and sudden death (see Table 3 for the mortality rates).
the proportion of smokers was very low. Thus, until the contrary is proved in prospective trials with sufficient power, the preventive effects of antihypertensive treatment should be considered to stand regardless of smoking status. In the EWPHE trial, smoking at randomization was not a significant cardiovascular risk factor. 30 In contrast, in the Syst-Eur trial, smoking nearly doubled the risk of total and cardiovascular mortality and combined fatal and nonfatal cardiovascular and cardiac end points (Tables 1 and 2 ). In the Medical Research Council trial in young adults with mild hypertension, 23, 24 untreated stroke rates were 2 to 3 times higher in smokers. Similarly, in the Australian Therapeutic Trial in Mild Hypertension (ATTMH), 31 smoking was associated with raised cardiovascular risk. The trials of antihypertensive drug treatment were not designed to provide direct evidence that stopping smoking would reduce risk but highlight the potential of cardiovascular prevention by persuading patients to stop smoking. Independent data [32] [33] [34] show that the excess risk conferred by smoking is reversible in middle-aged adults. Older people experience the highest rates of cardiovascular disease and therefore theoretically have the best prospect of short-term benefit from smoking cessation. The draft agreement between the attorneys general and the tobacco industry in the United States 35 requires the tobacco companies to contribute millions of dollars to campaigns to discourage teenage smoking but does not include specific measures to prove the reversibility of the deleterious effects of smoking on cardiovascular health in the elderly.
Some studies found a positive correlation between alcohol intake and stroke, particularly hemorrhagic stroke. 36, 37 However, prospective studies have demonstrated a U-shaped relationship, 38, 39 with nondrinkers having a higher relative risk of ischemic stroke than moderate drinkers (4-15 g/d), whereas the risk of ischemic stroke increased again in heavy drinkers. In contrast, for hemorrhagic stroke, there was an increased risk at all levels of alcohol intake. 39 Nearly 11% of the Syst-Eur patients consumed at least 1 alcoholic beverage per day. However, only 179 subjects (3.8%) consumed more than 20 g/d of alcohol. This probably explains why alcohol intake did not predict outcome in the Syst-Eur trial.
At median follow-up, 14.0% of the Syst-Eur patients whowithdrewfromactivetreatmentwereuntreated,whereas among the patients who withdrew from double-blind placebo, 58.1% switched to open-label treatment with antihypertensive drugs. 3 For this reason, the analysis by intention to treat was expected to produce lower levels of significance than the per-protocol analysis, which was confined to patientswhocontinuedtoreceiverandomizedtreatment.However, this expectation was entirely fulfilled only for total mortality (Table 3 ). In general, the intention-to-treat and perprotocol analyses generated remarkably similar results. This may be explained by the fact that, due to the early termination of the trial on February 14, 1997, median follow-up was only 3 months longer, while the analysis also accounted for the end points during open follow-up.
The benefit of antihypertensive treatment is usually expressed in relative terms as the percentage reduction in the event rate compared with the control group. However, this quantity may be misleading, because in absolute terms the number of patient-years of treatment required to prevent one event varies proportionally with the underlying risk as estimated from the event rate observed in the control group. 40, 41 Among 8 intervention trials in the elderly, [8] [9] [10] [11] [12] [13] 17 including the Syst-Eur trial (Figure 6 ), the absolute benefit with regard to all strokes and cardiovascular mortality was small in the group of older patients (Ն60 years) enrolled in the ATTMH 13 and the Medical Research Council trial 12 and large in the STOP-Hypertension trial. 10 The number of strokes or cardiovascular deaths prevented in these trials ranged from 10 12,13 to 74 10 and from 6 12,13 to 67 10 per 1000 patients treated for 5 years, respectively. In the analysis by intention to treat, the Syst-Eur results with respect to the number of strokes prevented were in close agreement with those reported by the SHEP trial. 17 In relative terms, the percentage reduction instrokeincidenceamountedto42%and36%, 17 respectively, while in both trials nearly 30 patients had to be treated for 5 years to prevent 30 strokes. For cardiovascular mortality, therelativebenefitintheintention-to-treatanalysisamounted to 27% and 20%, 17 respectively, while 5000 patient-years of treatment prevented 18 and 10 17 cardiovascular deaths. In conclusion, in elderly patients with isolated systolic hypertension,stepwiseantihypertensivedrugtreatment,starting with the dihydropyridine calcium channel blocker nitrendipine, improves prognosis. The per-protocol analysis suggested that, at the rates observed in the placebo group, treating 1000 patients for 5 years may prevent 24 deaths, 54 major cardiovascular end points, 29 strokes, or 25 cardiac end points. The benefit of treatment seemed to be universal, except for total and cardiovascular mortality, which were probably less reduced in very old patients.
